Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mibefradil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H known ✓ | O95180 | 10/20 | 1.00 |
| ▸ | CACNA1G known ✓ | O43497 | 1/20 | 1.00 |
| ▸ | CACNA1I known ✓ | Q9P0X4 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mibefradil SCHEMBL22968530 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL39551 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL7265837 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL30170543 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL29364574 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL29359482 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL7708100 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL2230258 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL908985 | 0.99 | MAPT (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL120810 | 0.99 | MAPT (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147575-A1 | Nitrate salts of antihypertensive medicines | NICOX S.A. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147575-A1 | Nitrate salts of antihypertensive medicines | NOS2, NOS1, NOS3 | CACNA1H 260/4885CACNA1G 184/4885CACNA1I 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.